Contineum Therapeutics (CTNM) Preferred Stock Liabilities (2023 - 2024)
Contineum Therapeutics (CTNM) posted quarterly Preferred Stock Liabilities of $192.6 million for Q1 2024, little changed quarter-over-quarter from $192.6 million in Q4 2023.
Powered by 
Analysis
Contineum Therapeutics (CTNM) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Contineum Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $192.6 million for Q1 2024.
- In Q1 2024, Preferred Stock Liabilities changed N/A year-over-year to $192.6 million; the TTM figure through Mar 2024 stood at $192.6 million (changed N/A YoY), while the FY2023 annual figure was $192.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2024 stood at $192.6 million, roughly flat from $192.6 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $192.6 million in Q4 2023, with the low at $192.6 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Contineum Therapeutics | 628.71 Mn | 628.71 Mn | - | - |